Bedrijfsoverzicht
TuHURA Biosciences, Inc. operates as a clinical stage immuno-oncology enterprise dedicated to developing novel technologies specifically for the treatment of cancer immunotherapies. The company focuses on advancing its lead product candidate, IFx2.0, which is an innate immune agonist engineered to overcome primary resistance associated with checkpoint inhibitors. This biotechnology firm functions within the healthcare sector and the biotechnology industry, positioning itself at the intersection of advanced medical research and therapeutic development. With a market capitalization of $144.32M and an employee base of 22, the company maintains a small-scale operational footprint typical of early-stage clinical entities. The current market cap reflects the market's valuation of its pipeline potential rather than established profitability, as the company has not yet generated sufficient revenue to derive a meaningful price-to-sales ratio, indicating its position as a capital-intensive venture reliant on future clinical success.
Financiële gezondheid
The financial statements for the trailing twelve months reveal a net income of $-30,060,332 and an EBITDA of $-28,045,056, while revenue data is unavailable. The substantial gap between the reported net income and the EBITDA figure highlights significant non-operating costs or interest expenses that impact the bottom line, suggesting a cost structure heavily influenced by financing costs or one-time charges rather than core operational inefficiencies. The company reports a free cash flow of $-4,757,422, which indicates a continuous outflow of capital required to sustain its R&D activities and clinical trial operations, thereby limiting its current financial flexibility to fund growth internally. Regarding profitability metrics, the gross margin, operating margin, and profit margin are all recorded at 0.0%, which is characteristic of a pre-revenue biotechnology company where costs are primarily research and development expenses rather than cost of goods sold. On the balance sheet, the company holds $3.62M in cash against $700,022 in debt, resulting in a debt-to-equity ratio of 3.34, which suggests a leveraged financial structure where equity is relatively low compared to total liabilities. Liquidity is constrained as evidenced by a current ratio of 0.78, indicating that current assets are insufficient to cover current liabilities without external financing or asset sales. Return on Equity stands at -169.2% and Return on Assets at -74.3%, metrics that reveal management has not yet generated positive returns on shareholder capital or total assets, a common but critical challenge for clinical-stage firms before product approval.
Waarderingsbeoordeling
Valuation multiples for TuHURA Biosciences, Inc. present a complex picture with a trailing P/E ratio of N/A and a forward P/E of -3.91. The disparity between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in future earnings that are currently negative, suggesting an expected trajectory where losses may persist or narrow depending on clinical milestones. The price-to-book ratio is 6.52, indicating that the market values the company's equity at a significant premium over its book value, likely reflecting the high potential value of its intellectual property and pipeline assets that are not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of N/A and an EV/EBITDA of -5.05, which suggest that traditional revenue-based or earnings-based valuation models are not applicable due to the lack of revenue and negative earnings. Price action shows a 52-week high of $4.44 and a 52-week low of $0.41, with the current share price trading in a range that reflects high volatility and uncertainty regarding the company's path to profitability. The beta is listed as N/A, which prevents a direct comparison of price volatility relative to the broader market using standard statistical measures, though the wide spread between the 52-week high and low suggests significant price instability.
Growth & Income
Growth metrics for the company show revenue growth year-over-year as N/A and earnings growth year-over-year as N/A, preventing a direct comparison of earnings growth speed relative to revenue. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm reinvests all available earnings and cash reserves back into its research and development efforts rather than distributing income to shareholders. The overall growth and income profile is defined by a complete absence of current cash returns to investors and a reliance on external capital markets to fund its expansion and clinical trials. This reinvestment strategy is typical for clinical stage biotechnology firms, where capital is directed toward achieving regulatory approval for products like IFx2.0 rather than providing immediate income, creating a high-risk, high-potential-reward scenario dependent on future successful market entry.